Medical studies link Cefepime to mortality risk and identify CFS respiratory causes

Recent medical studies have identified new risks and underlying causes for specific health conditions. An analysis of the antibiotic Cefepime, used for pneumonia and urinary tract infections, suggests a potential link to increased mortality in adults. The study found that 6.6% of patients receiving Cefepime died, compared to 6.2% of those receiving other beta-lactam antibiotics. While adults showed an 18% higher risk of mortality, no such increased risk was observed in children.

Separately, researchers at the Mount Sinai School of Medicine have discovered that 71% of patients with Chronic Fatigue Syndrome (CFS) exhibit hidden respiratory issues. The study, published in Frontiers in Medicine, indicates that patients often experience rapid breathing and respiratory dysfunction, such as shallow breaths. These issues may be caused by dysautonomia, a malfunction of the autonomic nervous system. Researchers suggest that respiratory interventions, including breathing exercises and light physical activity, could serve as new treatment approaches for CFS.